Farid Vij is President & GM of Invitaes Patient Network & Data division where he leads strategy, product and operations for the business. His core focus is building a two-sided platform that connects patients, providers and researchers through patient-consented data to help patients find better care options and advance research through real world evidence generation. Prior to Invitae, Farid was co-founder and COO at Ciitizen, a company focused on providing patients with access to their complete medical records. At Ciitizen, he drove the companys operations and go-to-market strategy, before leading its acquisition by Invitae in September 2021. Before Ciitizen, Farid held various commercial and operational roles at ZL Technologies, a big data company focused on harnessing unstructured information to drive critical privacy decisions for large organizations. Farid holds a BS in Economics from the Wharton School at the University of Pennsylvania. He enjoys angel investments in mission-focused companies and supporting education-focused non-profit organizations.
- Courtney McFall, UCSF
- Ben Rubin, UCSF
Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support.